TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00652522

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Medical Treatment
Description: Best medical treatment according to current guidelines for Management of Patients with Atrial Fibrillation and for Management of Chronic Heart Failure.
Study: NCT00717561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelox (Moxifloxacin, BAY12-8039)
Description: IV therapy: every 24 hours, patients will be administered a 400 mg moxifloxacin infusion over 60 minutes. Oral therapy: patients will be administered a single moxifloxacin 400 mg tablet, every 24 hours
Study: NCT01797003

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High tibial osteotomy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High tibial osteotomy
Study: NCT01554423

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Testing and Counseling
Description: Couples will receive information on the transmission and prevention of HIV and STIs, the meaning of test results, and health consequences.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Motivational Interview (BMI)
Description: The brief motivational interview (BMI) to be tested in the RCT in Pretoria is a one-session, 45 minute intervention that will coordinate three, 15-minute modules with one module each to (1) reduce hazardous drinking; (2) reduce illicit drug use; and (3) promote condom use.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Motivational Interview (BMI)
Description: The brief motivational interview (BMI) to be tested in the RCT in Pretoria is a one-session, 45 minute intervention that will coordinate three, 15-minute modules with one module each to (1) reduce hazardous drinking; (2) reduce illicit drug use; and (3) promote condom use.
Study: NCT00845260

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavior therapy (CBT).
Description: Self-help program and guidance by psychologist via e-mail during 10 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group CBT
Description: Group cognitive behavior therapy (CBT) during 10 weeks.
Study: NCT01554423

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Family and Cognitive Behavioral Therapy
Description: The IFCBT model is 6 sessions in length and coordinates the delivery of 4 cognitive-behavioral group couples' sessions with 2 individual couples' sessions to prevent HIV and STI co-infections among adult drug users. IFCBT targets HIV risk and protective factors that operate across multiple ecological systems. The four group couples' sessions coordinate Rational Emotive Therapy and Problem Solving Therapy strategies to reduce HIV risk behavior and promote protective behaviors. The two individual couples' sessions utilize structural and strategic approaches to promote adaptive communication and shared responsibility for condom use and gender equality and to directly address and reduce any form of abuse between partners when present.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Family and Cognitive Behavioral Therapy
Description: The IFCBT model is 6 sessions in length and coordinates the delivery of 4 cognitive-behavioral group couples' sessions with 2 individual couples' sessions to prevent HIV and STI co-infections among adult drug users. IFCBT targets HIV risk and protective factors that operate across multiple ecological systems. The four group couples' sessions coordinate Rational Emotive Therapy and Problem Solving Therapy strategies to reduce HIV risk behavior and promote protective behaviors. The two individual couples' sessions utilize structural and strategic approaches to promote adaptive communication and shared responsibility for condom use and gender equality and to directly address and reduce any form of abuse between partners when present.
Study: NCT01743131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: Arm B-investigational prophylaxis with abatacept, a calcineurin inhibitor and methotrexate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT01940679

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: encapsulated 600 mg EPA/DHA
Description: encapsulated 600 mg EPA/DHA

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: encapsulated 600 mg EPA/DHA
Description: encapsulated 600 mg EPA/DHA

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: encapsulated 600 mg EPA/DHA
Description: encapsulated 600 mg EPA/DHA

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: encapsulated 600 mg EPA/DHA
Description: encapsulated 600 mg EPA/DHA
Study: NCT03026452

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: US-guided RFA
Description: The investigators used percutaneously US-guided radiofrequency ablation for patients with small hepatocellular carcinoma,and estimated the safety and efficacy of this treatment through 2-year follow-up of US/CEUS/CT/MRI and the tumor markers.
Study: NCT00717561

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftriaxone; Azithromycin; Amoxicilline/clavulanate; Clarithromycin
Description: IV therapy: every 24 hours patients will be administered a 2 g ceftriaxone infusion over 30 minutes. Following the infusion with ceftriaxone, patients will be administered a 500 mg azithromycin infusion over 180 minutes.Oral therapy: every 8 hours patients will be administered a 1000 mg amoxicillin/clavulanic acid tablet. Every 12 hours patients will be administered a 500 mg clarithromycin tablet.
Study: NCT04392908

Intervention type: OTHER
Intervention: Communication memory
Description: All groups will undergo audio-recorder interviews. Only adults will complete a self-report questionnaire on phenomenological aspects of autobiographical memories.

Intervention type: OTHER
Intervention: Communication memory
Description: All groups will undergo audio-recorder interviews. Only adults will complete a self-report questionnaire on phenomenological aspects of autobiographical memories.

Intervention type: OTHER
Intervention: Communication memory
Description: All groups will undergo audio-recorder interviews. Only adults will complete a self-report questionnaire on phenomenological aspects of autobiographical memories.
Study: NCT00141544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esterified estrogens 1.25 mg and methyltestosterone 2.5 mg
Description: ESTRATEST® administered orally QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esterified estrogens 1.25 mg
Description: Esterified estrogens 1.25 mg administered orally QD
Study: NCT00138853

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tibial component
Description: Tibial component inserted at the time of surgery

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tibial component
Description: Tibial component inserted at the time of surgery
Study: NCT03287830

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text message influenza vaccine reminders
Description: Text message reminders for second dose of influenza vaccination
Study: NCT00945594

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cystoscopy
Description: A 16 F flexible cysto urethroscope (Storz, Culver city, CA) is used for flexible cystoscopy. When rigid cystoscopy is performed, a 17F, 70° scope (Storz, Culver city, CA)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cystoscopy
Description: A 16 F flexible cysto urethroscope (Storz, Culver city, CA) is used for flexible cystoscopy. When rigid cystoscopy is performed, a 17F, 70° scope (Storz, Culver city, CA)
Study: NCT04904991

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chan-Chuang qigong
Description: This study applied the Chan-Chuang qigong program, which was a modified form of the manual of Chan-Chuang qigong (Yeh et al., 2006), to tailor to patients with cognitive impairment. The Chan-Chuang qigong program included warmup prior to qigong practice, preparation for qigong practice, core qigong of four moves, and cool down after qigong practice.~The movements should be repeated and maintained for 10 minutes per time, 3 time a day (Yeh et al., 2006), totally 90 minutes per week, for 3 months. The guideline booklet of Chan-Chuang qigong (Chen et al., 2019; Chuang, Yeh, \& Chung, 2017) was modified and provided to the participants, which had major sections of introduction to qigong, preparation and precautions, practical procedures with description and photos, normal physical reactions from practicing core Chan-Chuang qigong, precautions of daily life, a confirmation sheet, and a checklist of qigong performance.
Study: NCT03756636

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Underwater mucosectomy with submucosal injection of viscous solution -SIC 8000 (EleviewTM)
Description: Underwater mucosectomy with submucosal injection of viscous solution -SIC 8000 (EleviewTM)
Study: NCT02168309

Intervention type: DRUG
Group type: OTHER
Intervention: Labetalol
Description: Titrate up for blood pressure control
Study: NCT04161963

Intervention type: DEVICE
Intervention: SD-OCT
Description: Optical Coherence Tomography of the maculy with Heidelberg Spectralis SD-OCT

Intervention type: DEVICE
Intervention: SD-OCT
Description: Optical Coherence Tomography of the maculy with Heidelberg Spectralis SD-OCT
Study: NCT02168309

Intervention type: DRUG
Group type: OTHER
Intervention: Nifedipine
Description: Titrate up to achieve blood pressure control
Study: NCT02401932

Intervention type: OTHER
Intervention: Hemophagocytosis
Description: Best supportive care and immunosuppressive treatments
Study: NCT01433185

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text message
Description: Text messages sent to women before and after delivery
Study: NCT00989755

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Fax to Quit (F2Q)
Description: Clinics in this group receive electronic and hard copies of all materials necessary for implementing Fax to Quit within their clinics.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fax to Quit (F2Q)
Description: Clinics in this group receive electronic and hard copies of all materials necessary for implementing Fax to Quit within their clinics.
Study: NCT04306692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myo-inositol
Description: 2 x 1 bag per day, per os (subjects can take myo-inositol during the meal but it is not obliged).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene Citrate
Description: Each tablet contains 50 mg of clomiphene citrate which means 33,9 mg of clomiphene. Other constituents are sucrose, lactose monohydrate, corn starch, pregelatinized starch, yellow iron oxide (E172) and magnesium stearate (E470b).~Dosing: 1 tablet per day from cycle day 3 until 7 (extremes included), stepping up until a maximum dose of 3 tablets per day for 5 consecutive days.
Study: NCT01008098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: escitalopram (lexapro)
Description: 0 - 4 week: 10 mg escitalopram a day 5 - 8 week: 20 mg escitalopram a day
Study: NCT02642614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1026706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1026706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1026706
Study: NCT04161963

Intervention type: DEVICE
Intervention: SD-OCT
Description: Optical Coherence Tomography of the maculy with Heidelberg Spectralis SD-OCT

Intervention type: DEVICE
Intervention: OCT-A
Description: swept source Optical Coherence Tomography Angiography with Zeiss Plex Elite 9000 of the macula

Intervention type: DEVICE
Intervention: OCT-A
Description: swept source Optical Coherence Tomography Angiography with Zeiss Plex Elite 9000 of the macula

Intervention type: DEVICE
Intervention: OCT-A
Description: swept source Optical Coherence Tomography Angiography with Zeiss Plex Elite 9000 of the macula
Study: NCT01329796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lignocaine
Description: Intrauterine flushing, pertubation, three treatments given preovulatory at cycle day 6-12 in three sequential menstrual cycles.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ringers Solution
Description: Intrauterine flushing, pertubation, given preovulatory at cycle day 6-12 in three sequential menstrual cycles.
Study: NCT02337530

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Selumetinib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Selumetinib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Study: NCT02642614

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: For blinding purposes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: For blinding purposes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: For blinding purposes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For blinding purposes
Study: NCT01148823

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Incisions covered for 1 day
Description: Dressing was removed on the first postoperative day.
Study: NCT04545736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin hydrochloride
Description: Metformin is commercially produced in immediate and extended release. Participants will receive an immediate release formulation of metformin of 500mg daily at study entry. This dose will be titrated up weekly in 500mg increments to reach a goal of 2000mg daily maximum. Once participants \>=17 years of age reach 2000mg metformin immediate release they will switch to an extended-release formulation (1000mg twice a day by mouth). Participants \>= 17 years of age that cannot tolerate 2000mg will be permitted to reduce their daily dose to a minimum of 1000mg/day. Because metformin extended release is not FDA-approved for children under the age of 17, participants under 17 will remain on the immediate release formulation. For these participants who remain on standard formulation, the maximum tolerated dose between 1000mg and 2000mg/day will be given.
Study: NCT01148823

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Incisions covered for 6 days
Description: Dressing was removed on the 6th postoperative day.
Study: NCT02090660

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ICG Localization with Spy thoracoscope localization
Study: NCT00464087

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Switching from Fondaparinux to Bivalirudin or Unfractionated Heparin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Switching from Fondaparinux to Bivalirudin or Unfractionated Heparin
Study: NCT03186222

Intervention type: DIAGNOSTIC_TEST
Intervention: blood sample
Description: Serum PRL levels are measured using ELISA assay kit in both groups and correlated with severity of acne in acne group.~The genomic DNA from peripheral leukocytes is extracted. Genotyping of 1149G/T single nucleotide polymorphism (SNP) PRL extrapituitary promoter is done in acne patients and healthy individuals (control group) using PCR-RFLP method.

Intervention type: DIAGNOSTIC_TEST
Intervention: blood sample
Description: Serum PRL levels are measured using ELISA assay kit in both groups and correlated with severity of acne in acne group.~The genomic DNA from peripheral leukocytes is extracted. Genotyping of 1149G/T single nucleotide polymorphism (SNP) PRL extrapituitary promoter is done in acne patients and healthy individuals (control group) using PCR-RFLP method.
Study: NCT01831544

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HeartWare MVAD® System
Description: The HeartWare MVAD® System consists of a small, wearless, continuous flow pump and associated surgical tools and implant accessories, peripheral components which control and power the system, and a monitor which allows for programming and monitoring of the system
Study: NCT03628703

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive TMS
Description: Repetitive Intermittent Theta-Burst Transcranial Magnetic Stimulation over the right Pre-supplementary Motor Area
Study: NCT03187093

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vortioxetine
Description: 10-20 mg once daily for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: 10-20 mg once daily for 8 weeks
Study: NCT03966378

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Grape seeds extract
Description: Grape seeds extract powder

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Casein-phosphopeptide/amorphous-calcium phosphate
Description: CPP-ACP paste
Study: NCT02899988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT03785431

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PCI with Phantom Bioresorbable Scaffold
Description: Once baseline angiography is performed and all eligibility criteria are met, the patient is included in the study. The target lesion should be crossed with a standard coronary guidewire. Next, the NIRS/IVUS and OCT probe is inserted and a pullback is being performed to evaluate the lesion and vessel morphology. The predilatation with 1:1 non-compliant or semi-compliant balloon is mandatory. Thereafter the scaffold should be inserted and position across the target lesion. Lesions up to 14 mm should be covered with the 18 mm device, for lesions of 15-20 mm a 24 mm device should be used. The scaffold will be deployed with intent to achieve the inner diameter to the reference vessel ration of 1:1 using a single inflation. Post-dilatation using a non-compliant balloon should be performed to achieve complete scaffold apposition and reduce the residual angiographic stenosis below 20%. The final NIRS/IVUS and OCT of the target vessel should be performed.
Study: NCT04492618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib cream 1.5%, topical application will be used twice daily on lesions of Necrobiosis Lipoidica
Study: NCT02352714

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracervical Nerve Block
Description: Block randomization to receive lidocaine paracervical nerve block vs sham cervical block

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham Paracervical Block
Description: Block randomization to receive lidocaine paracervical nerve block vs sham cervical block
Study: NCT02062034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ubiquinone
Description: 400mg daily of oral ubiquinone for 24 weeks
Study: NCT02337530

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Study: NCT02062034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combined antioxidant therapy
Description: (1 mg copper, 20 mg zinc, 180 mg vitamin C, 30 mg vitamin E, 1 mg zeaxanthin, 4 mg astaxanthin, 10 mg lutein) daily of oral, all of them in one Tablet for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100 mg of oral placebo with identical appearance, form, size than ubiquinone and antioxidant combined therapy for 24 weeks
Study: NCT00478569

Intervention type: DRUG
Intervention: Parathyroid Hormone (PTH) (1-84)
Description: Adherence to PTH(1-84) treatment in Usual Clinical Settings
Study: NCT03562481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% Buffered Lidocaine 1:100,000 Epinephrine
Description: A single IAN block with 3cc 1% Buffered Lidocaine (30mg) 1:100,000 Epinephrine using the Halstead technique.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% Buffered Lidocaine 1:100,000 Epinephrine
Description: A single IAN block with 3cc 1% Buffered Lidocaine (30mg) 1:100,000 Epinephrine using the Halstead technique.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% Unbuffered Lidocaine 1:100,000 Epinephrine
Description: A single IAN block with 3cc 2% Unbuffered Lidocaine (60mg) 1:100,000 Epinephrine using the Halstead technique.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% Unbuffered Lidocaine 1:100,000 Epinephrine
Description: A single IAN block with 3cc 2% Unbuffered Lidocaine (60mg) 1:100,000 Epinephrine using the Halstead technique.
Study: NCT02664441

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exenatide
Description: Weekly injections of active drug.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Weekly placebo injections
Study: NCT03905187

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified CR
Description: Stress management involved modified cardiac rehabilitation

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Traditional CR
Description: Traditional cardiac rehabilitation

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Education
Description: Education
Study: NCT01486914

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: Single dose of each formulation administrated subcutaneously (s.c., under the skin) at two separate dosing visits

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: Single dose of each formulation administrated subcutaneously (s.c., under the skin) at two separate dosing visits
Study: NCT02753101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]-FTC-146
Description: 10 mCi± 1 mCi of \[18F\]FTC-146 intravenously
Study: NCT01640145

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Protein
Description: Whey protein intake

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Protein
Description: Whey protein intake

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Exercise
Description: Unilateral low intensity exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Unilateral low intensity exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Unilateral low intensity exercise
Study: NCT02337530

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Study: NCT03989453

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chi Kung
Description: The duration of the intervention is 12 weeks, with 2 sessions per week of Chi Kung. Each session lasts approximately 1 hour and is structured in three parts: initial warm-up (Based on breathing and concentration exercises), of 10 minutes duration, a 40-45 minute Chi Kung session and finally 10 minutes of guided relaxation.